Alfuzosin

Alfuzosin

Alfuzosin
Systematic (IUPAC) name
N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide
Clinical data
Trade names Uroxatral
AHFS/Drugs.com
MedlinePlus
Pregnancy
category
  • AU: B2
  • US: B (No risk in non-human studies)
Legal status
Routes of
administration
Oral
Pharmacokinetic data
Bioavailability 49%
Protein binding 82%-90%
Metabolism Hepatic (CYP3A4-mediated)
Biological half-life 10 hours
Excretion Fecal (69%) and renal (24%)
Identifiers
CAS Registry Number  YesY
ATC code G04
PubChem CID:
IUPHAR/BPS
DrugBank  YesY
ChemSpider  YesY
UNII  YesY
KEGG  YesY
ChEBI  YesY
ChEMBL  YesY
Chemical data
Formula C19H27N5O4
Molecular mass 389.449 g/mol
 YesY   

Alfuzosin (INN, provided as the hydrochloride salt) is a pharmaceutical drug of the alpha-1 blocker class. As an antagonist of the alpha-1 adrenergic receptor, it works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate. It is thus used to treat benign prostatic hyperplasia (BPH).

Alfuzosin is marketed in the United States by Sanofi Aventis under the brand name Uroxatral and elsewhere under the tradename Xat or Xatral, and in Egypt under name of Prostetrol. Alfuzosin was approved by the FDA for treatment of BPH in June 2003.

Side effects

The most common side effects are dizziness (due to postural hypotension), upper respiratory tract infection, headache, and fatigue.abdominal disturbances.

Contraindications

Alfuzosin should be used with caution in patients with severe renal insufficiency, and should not be prescribed to patients with a known history of QT prolongation who are taking medications known to prolong the QT interval.

External links

  • Uroxatral (manufacturer's website)
  • Sandoz Alfuzosin (Canadian product sheet)
  • Alfuzosin (General information from the NIH)